
Medline Inc (MDLN) Stock Forecast & Price Target
Medline Inc (MDLN) Analyst Ratings
Bulls say
Medline's financial performance for the 12-month period ending December 2025 reflects significant growth, with sales revenue rising 11.47% year-over-year from $25.51 billion to $28.43 billion and an increase in return on capital from 7.22% to 7.44%. The company achieved $2.4 billion in new customer signings in 2025, driven by strong demand for its Medline-branded products and supply chain solutions, which now account for nearly half of its revenue and over 80% of its sales segment. Projections indicate further revenue growth of 257.98% in the next twelve months, reflecting the positive momentum and robust market positioning supported by Medline's extensive distribution network and manufacturing capabilities.
Bears say
Medline's financial outlook is impaired by a significant 220.79% year-over-year decline in Economic Profit, shifting from a gain of $345.1 million to a loss of $416.9 million, primarily due to equity cost measurements following its IPO. Additionally, the company faced a 12.66% decrease in Net Operating Profit After Tax (NOPAT), falling from $2.45 billion to $2.14 billion, along with a 4.48% decline in Economic Operating Cash Flow (EBITDAR), which decreased from $3.71 billion to $3.54 billion over the last twelve months. The challenges of low margins in the healthcare sector, coupled with increased competition and potential disruptions in supply chains, raise concerns about Medline's ability to maintain growth and market share moving forward.
This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.
Medline Inc (MDLN) Analyst Forecast & Price Prediction
Start investing in Medline Inc (MDLN)
Order type
Buy in
Order amount
Est. shares
0 shares